ELAN vs IDXX
ELAN: Elanco is a pure-play animal health leader focused on innovating treatments and wellness solutions for pets and livestock worldwide. IDXX: IDEXX Laboratories is a global pet healthcare leader providing essential diagnostic, laboratory, and software solutions to veterinary practitioners worldwide.
Side-by-side fundamentals
| Metric | ELAN | IDXX | Edge |
|---|---|---|---|
| Price as of 2026-10-20 close | $22.70 | $557.93 | |
| Market cap | $11.3B | $44.0B | |
| P/E as of 2026-10-20 | n/a | 39.21 | |
| PEG as of 2026-10-20, 3-year EPS CAGR to FY2025 | n/a | 2.22 | |
| Net margin FY2025, SEC XBRL | -4.9% | +24.6% | IDXX higher |
| Gross margin FY2025, SEC XBRL | +55.0% | +61.8% | IDXX higher |
| Operating margin FY2025, SEC XBRL | n/a | +31.6% | |
| ROE FY2025, SEC XBRL | -3.5% | +66.0% | IDXX higher |
| ROA FY2025, SEC XBRL | -1.7% | +31.6% | IDXX higher |
| Debt / equity filed borrowings, leases excl., balance sheet 2026-06-30 | 0.56 | 0.28 | IDXX lower |
| Revenue growth (YoY) FY2025, SEC XBRL | +6.2% | +10.4% | IDXX higher |
| Revenue CAGR (3y) SEC XBRL | +2.2% | +8.5% | IDXX higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 1.25 | 0.93 | |
| 1-year return as of 2026-10-20 close | +4.5% | -13.3% | ELAN higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.